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Abstract
Erectile dysfunction is a known and much-dreaded functional consequence of radical 
prostatectomy. Dr. Patrick Walsh pioneered the nerve-sparing radical retropubic pros-
tatectomy in the early 1980s, which has mitigated the morbidity of this surgery. Post-
operative potency rates range widely from 20 to 80%, however, and depend on myriad 
factors including age, preoperative potency, and degree of nerve-sparing during surgery. 
Over the past four decades several developments have continued to offer hope to patients 
and clinicians alike, including refined understanding of cavernosal nerve neuroanatomy, 
beneficial modifications in surgical technique, as well as the advent of robotic surgery. 
Furthermore, multiple pre- and post-operative penile rehabilitation techniques using 
mechanotherapy and pharmaceuticals have also improved functional recovery. This 
paper examines erectile dysfunction as a consequence of radical prostatectomy, including 
the physiology of erections, the pathophysiology of post-operative erectile dysfunction, 
novel surgical techniques to enhance neurovascular bundle preservation, and penile reha-
bilitation strategies involving hyperbaric oxygen, neuroprotective pharmaceuticals, dehy-
drated human amnion-chorion membrane allografts, and mesenchymal stem cell therapy.
Keywords: erectile dysfunction, nerve-traction injury, nerve-sparing radical 
prostatectomy, penile rehabilitation, amnion-chorion membrane therapy,  
stem cell therapy
1. Introduction
Erectile dysfunction is a known and much-dreaded functional consequence of surgery for pros-
tate cancer. Although surgeons may cite oncologic control as the paramount component of the 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
“Trifecta” (i.e. cancer cure, continence, and potency), many patients cite recovery of erectile 
function as the true measure of treatment success. In the early days of radical prostatectomy, 
post-operative potency rates were poor, and in fact largely non-existent. With the advent of 
nerve-sparing anatomic radical retropubic prostatectomy, a surgical approach pioneered by 
Dr. Patrick Walsh, the prospect of post-operative recovery of potency became not only a possibility 
but a reality for many men. The myriad factors that influence a patient’s likelihood of sexual 
function recovery after both open and robotic radical prostatectomy have been examined and 
published in the literature. Also, there has been much investigation into the pathophysiology of 
iatrogenic erectile dysfunction (i.e. neurapraxia and nerve-traction injury) in the form of in vitro, 
pre-clinical animal studies and even translational studies with randomized human subjects. 
Given the pivotal importance of erectile function in a patient’s perceived post-operative quality 
of life, there is much interest in the optimization of perioperative techniques to spare the integ-
rity of the cavernous nerves and to develop efficacious mechanical and pharmacologic penile 
rehabilitation programs. Such programs employ an increasingly sophisticated arsenal of medi-
cal technologies such as pluripotent stem cell therapy, cytokine-rich human amnion-chorion 
membrane allograft, and even reappropriation of pharmacotherapies traditionally used for 
other disease states that have been found to have neuroprotective properties. This chapter will 
examine the evolution in the understanding of erectile dysfunction as a consequence of radical 
prostatectomy and examine novel strategies for prevention and amelioration of this condition.
2. Physiology of erections
2.1. Anatomy
The central role of smooth muscle dynamics in the corpora cavernosa in the development 
of erections was first elucidated in the 1980s [1]. Identification of nitric oxide (NO) as the 
principle neurotransmitter for tumescence and phosphodiesterases for detumescence were 
also major milestones with well-known pharmacologic ramifications. Anatomically, beneath 
the Buck’s fascia, the corpora cavernosa are surrounded by the two-layered tunica albuginea, 
a reticulated network of collagen and elastin fibers that provides structural support during 
tumescence. The outer layer serves to compress the obliquely oriented emissary veins during 
tumescence that results in the “bottle-neck” effect of slower outflow than inflow that is essen-
tial for maintenance of an erection (Figure 1) [2]. The penile arterial supply arises from inter-
nal pudendal artery, which then gives rise to the common penile artery that branches into the 
dorsal, cavernous, and bulbourethral arteries. The cavernous arteries are responsible for the 
engorgement of the corpora cavernosa during tumescence. Accessory pudendal arteries may 
also be present in up to 4–25% of patients and these arise from the external iliac, obturator, 
vesical, and femoral arteries. Their preservation has been shown to be important for recovery 
of erectile function after radical prostatectomy [3, 4].
2.2. Neuroanatomy
The vasomotor tone of the cavernous arteries is regulated by the autonomic cavernous nerves. 
They are the nerves that are being described during “nerve-sparing” techniques during radical 
Prostatectomy130
prostatectomy. These nerves arise as an extension from the parasympathetic pelvic splanch-
nic nerves that originate from the pelvic plexus (S2–S4) located on either side of the rectum 
(Figure 2). These nerves innervate the endothelium of the cavernous sinuses and release acetyl-
choline which inhibits adrenergic neurons and stimulates NO release from endothelial cells [5]. 
NO increases intracellular production of cGMP with resultant decline in intracellular calcium 
and relaxation of the cavernous smooth muscle. Phosphodiesterase 5 is responsible for the 
degradation of cGMP and is the target of the well-known medications for erectile dysfunction.
Since Walsh and Donker pioneered the nerve-sparing radical prostatectomy in 1982, there has 
been much debate about the nature and trajectory of these nerves [6, 7]. These nerves have 
been found to travel as a latticework of delicate fibers principally along the posterolateral 
and lateral aspects of the prostate, but with some fibers coursing ventrally as well. Invaluable 
work in human cadavers by several investigators has elucidated precise position and orienta-
tion of these nerves to optimize their preservation during radical prostatectomy.
Figure 1. Anatomy of subtunical emissary veins as the basis for tumescence. Reprinted without changes from Molodysky 
et al. [2] https://creativecommons.org/licenses/by-nc-nd/3.0/.
Preventing Erectile Dysfunction after Radical Prostatectomy: Nerve-Sparing Techniques, Penile…
http://dx.doi.org/10.5772/intechopen.79398
131
Costello et al. used cadaver models to identify three functional domains of the neurovascular 
bundle (NVB): the posterior and posterolateral component runs within the Denonvilliers’ 
fascia and the pararectal fascia and innervates the rectum; the lateral component supplies the 
levator ani, and the cavernosal nerves lie along the posterolateral surface [8, 9]. Furthermore, 
Lunacek et al. showed that the cavernous nerves are displaced more anteriorly and splay 
along the lateral aspect of the prostate like a curtain [10]. These findings inspired the “cur-
tain dissection” technique of high anterior release as well as the technique of preserving the 
lateral prostatic fascia within which the neurovascular bundle travels known as the “Veil of 
Aphrodite” technique to maximize the number of nerve fibers preserved [10, 11]. Dr. Ashutosh 
Tewari has conceptualized the neuroanatomy as consisting of a tri-zonal neural architecture, 
comprised of the proximal neurovascular plate (PNP), predominant neurovascular bundle 
(PNB), and accessory neural pathways (ANP) [12]. The PNP is synonymous with the pelvic 
plexus and the PNB is the traditionally described NVB, which is enclosed within the layers 
of levator fascia and/or lateral pelvic fascia. The nerves are situated in a “hammock-like” 
distribution rather than a distinct, isolated structure (Figure 2).
Further anatomical studies have demonstrated that a significant proportion of the nerves are 
situated on the anterior surface of the prostate, 21.5–28.5% [13] and 19.9–22.8% (Figure 3) [14]. 
Structural configurations range from round and bundle-like to more widely distributed splay-
like [15]. Ganzer et al. employed computerized planimetry software to analyze the topogra-
phy of the nerves on whole-mount pathologic sections obtained during non-nerve-sparing 
radical prostatectomy [16]. Total nerve surface area was most concentrated dorsolaterally 
(74.5–84.1%), but up to 39.9% of nerve surface area was found ventrolaterally. These corre-
spond to the ANPs described by Dr. Tewari’s group, who found them in 41% of the cadavers 
[12]. It is possible that all of these nerves are not responsible for erections. Subsequent studies 
in electrophysiologic stimulation have shown cavernosal pressure responses with stimulation 
at all positions of the midprostate between the 1:00 and 5:00 positions for all patients, suggest-
ing their role in potency [17]. The precision vs. degree of electrical spread of such electrical 
stimulation may represent a limitation of this testing. Conversely, Costello et al. reported that 
Figure 2. Pelvic plexus and cavernous nerve anatomy. P = prostate; U = urethra; R = rectum; PNP = proximal neurovascular 
plate; ANP = accessory neurovascular plate; PNB = predominant neurovascular bundle. Reprinted from Tewari et al. [12].
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significantly parasympathetic nerve fibers only account for 4–6.8% of nerves on the anterolat-
eral aspect of the prostate [18]. These findings were corroborated by Ganzer et al., who used 
immunohistochemistry to distinguish between parasympathetic and sympathetic nerves. 
They reported that only 14.6% of the parasympathetic nerves resided above a horizontal line 
drawn at the prostate base and only 1.5% above a horizontal line at the apex [19].
How these anatomical findings impact the functional outcomes of the various nerve-sparing 
approaches described below, some of which advocate for high anterior release of the prostatic 
fascia, is interesting to consider (see Section 5.2).
3. Pathophysiology of post-prostatectomy erectile dysfunction
There are several acute and chronic factors that contribute to decline in erectile function after 
surgery for prostate cancer. These factors may be classified as vasculogenic, neurogenic, 
and even psychological. The burden of cancer diagnosis, treatment, and need for long-term 
PSA monitoring, along with recovery from surgery, implications on self-image, awareness 
of mortality, and perceived or actual reduction in penile length represent a constellation of 
psychosocial factors that may contribute to ED.
The role of accessory pudendal arteries in vasculogenic erectile function has been described 
above. Chen et al. has also implicated the veins that travel longitudinally within the layers of 
the tunica albuginea. His group have reported that ligation of the DVC during prostatectomy 
results in dilatation of these veins which results in veno-occlusive dysfunction [20].
The vascular sequelae of radical prostatectomy were investigated by Mulhall et al., who 
reported cavernosometry and/or penile duplex ultrasonography [21]. They found arterial 
Figure 3. Whole-mount anatomy of neurovascular bundle (NVB) topography on the prostate. A. NVB concentrated at 
posterolateral aspect of prostate (S-100 stain) B. NVB are more widely distributed to ventral aspect of prostate (S-100 
stain). Reprinted from Lee et al. [14].
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insufficiency in 59% and venous leakage in 26% of men after bilateral nerve-sparing RRP who 
had excellent pre-operative erectile function. Normal vascular status was found in 35% of 
men. Return to penetrative function was correlated with the vascular status, with 47% return 
if normal status, 31% in arteriogenic insufficiency, and only 9% with veno-occlusive dysfunc-
tion at 12 months. They also reported that the longer the duration of erectile dysfunction, the 
higher the risk of venous leakage. Zelefsky et al. reported venous leakage in 52%, arterial 
insufficiency in 32%, and neurogenic dysfunction in 12% [22]. Montorsi et al. found a higher 
proportion of patients with veno-occlusive disease in their randomized study of intracav-
ernous alprostadil after open RP: 67% veno-occlusive dysfunction, 17% arterial insufficiency, 
17% normal vascular dynamics [23].
3.1. Neurapraxia
The neurogenic basis for erectile dysfunction implicates the cavernous nerve architecture. 
Preservation of these architectural substrates may not be sufficient alone to engender recovery 
of post-operative function, as suggested by the well-documented latency period between sur-
gery and functional recovery. This latency ranges from 6–24 months and has been suggested 
to be the result of nerve-traction injury from the physical manipulation/handling during sur-
gery and resultant neurapraxia and axonotmesis [1, 24, 25].
Intraoperative manipulation and injury to the cavernosal nerves results in hemodynamic 
and histologic changes within the penis, which manifest clinically as erectile dysfunction. 
This injury may result from mechanical or thermal sources. Iatrogenic traction on the deli-
cate neurovascular tissue can cause-stretch induced nerve injury and resulting dysfunction. 
Neuropathies may be classified into three histologic groups: neurapraxia, axonotmesis, and 
neurotmesis. Neurapraxia is the least severe and is characterized intact neural structural 
elements, but there may be ischemia and/or demyelination which leads to signal conduction 
block. Functional deficits in peripheral nerves manifest as motor, proprioceptive, and soft 
touch deficiencies, but these usually resolve in a few weeks (up to 12 weeks) [26]. The next 
level of injury is axonotmesis in which axons and their myelin sheaths over long segments 
of nerve are disrupted, while supporting structures such as the endoneurium are left intact 
[27]. There is consequent Wallerian degeneration distal to the level of injury and proximal 
axonal degeneration to the next node of Ranvier. Since the endoneurial tubes remain intact, 
recovery should be complete after a matter of several months but may not be complete. Frank 
transection of the nerve is termed neurotmesis, in which the endoneurial tubes and con-
nective tissue components are disrupted. Intraneural fibrosis develops and impairs axonal 
regeneration and thus inhibits nerve functional recovery. Peripheral nerve regeneration is 
mediated by multiple factors including neurotrophic factors, extracellular matrix, and intact 
cellular components of the nervous system (i.e. endoneurium) [28]. Tissue trauma from sur-
gery also generates an inflammatory response and oxidative stress around the degenerating 
axons with results in chromatolysis (degradation of the protein synthesizing infrastructure 
of the neuronal cell body) [29].
Nerve injury may have a vasculogenic etiology as well. Nerve ischemia may be a result of direct 
compression injury or stretch (“traction”) injury, which produces a reduction in cross-sectional 
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area and resultant compression of the vasculature [27]. Traction disrupts and occludes small-
sized arteries traveling with the nerves (vasa nervorum) which supply pelvic tissues as well 
as the nerves themselves. Biochemically within the cavernosal smooth muscle cells, hypoxia 
induces production of superoxide which initiates oxidative reactions and attacks surrounding 
molecules to produce more free radicals. Oxygen free radicals in the setting of a nitric-oxide 
containing environment tends to combine to form peroxynitrite (O═NOO-) which is highly 
neurotoxic. Exposure of nerves to this compound leads to rapid excitation, excitotoxicity, and 
degeneration in the acute setting. Nitric oxide bioavailability is thereby reduced in this setting, 
which further impacts penile smooth muscle relaxation and exacerbates the hypoxic conditions.
3.2. Thermal injury
The importance of athermal dissection has been reinforced as classic teaching during 
nerve-sparing radical prostatectomy. The precise functional deficits induced by monopolar 
or bipolar cautery has been investigated in a canine model [30]. A total of 12 dogs were 
divided into four groups of neurovascular bundle dissection: Group 1, suture ligatures; 
Group 2, monopolar electrocautery; Group 3, bipolar electrocautery; Group 4, ultrasonic 
shears. Peak intracavernous pressures in response to distal cavernous nerve stimulation 
immediately post-op and at 2 weeks showed an attenuated response compared to controls 
(74–91% decrease and 93–96% decrease, respectively). In the dogs where electrocautery was 
employed, there was in fact almost no rise in the intracavernous pressure in response to 
stimulation. The findings in this study were presented in the context of having spared the 
contralateral neurovascular bundle from any dissection. Their results may have been even 
more dramatic if thermal energy had been used bilaterally. The follow-up was also admit-
tedly short in this series at 2 weeks post-op only. Much longer durations at 6-, 12-, and 
even 24 months would be helpful to determine the long-term impact of thermal energy on 
recovery of potency (see Section 5.6).
This very objective was explored in humans after robotic prostatectomy, demonstrating 
delayed recovery after 12–18 months, but with 68% of bilateral nerve-sparing patient ulti-
mately recovering function at 24 months [31] (see Section 5.3).
3.3. Chronic cavernosal tissue changes
In the chronic phase of injury, the persistent loss of nerve signal conduction results in loss 
of spontaneous nocturnal erections and relative cavernosal ischemia. The pathophysiologic 
consequence is cavernosal smooth muscle apoptosis, upregulation of TGF-beta and collagen 
deposition within the corpora [32–35]. Cavernous neurotomy studies in rats have demon-
strated that corporal smooth muscle apoptosis begins 1 day after injury and peaks within 
the first week [34]. This fibrotic reaction impairs full expansion of the venous sinuses within 
the tunica and failure to adequately compress the emissary veins against the tunica. The 
result is “veno-occlusive dysfunction” in which the venous outflow occurs with the same 
velocity as arterial inflow. In this setting, tumescence is unable to be achieved or maintained. 
Furthermore, there is anatomical loss of penile length and girth as a result of the cavernosal 
smooth muscle fibrosis.
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3.4. Sympathetic disinhibition
Erectile function is not only the result of parasympathetic input, but a dynamic interplay between 
enhanced parasympathetic and inhibited sympathetic function. The role of adrenergic, sympa-
thetic signals in ejaculation and detumescence have been well-established [36]. The adrenergic sys-
tem essentially inhibits tumescence via the release of presynaptic norepinephrine (NE) that binds 
to postsynaptic α1- and α2-adrenergic receptors that induce penile arterial and cavernosal smooth 
muscle contraction. Also, the activation of presynaptic adrenergic receptors on the parasympa-
thetic nerves inhibits release of NO [37]. The α1 receptor subtype is predominant in human erectile 
tissue, and furthermore α1A and α1D are more common than α1B in humans [38, 39]. Neurogenic 
contractile responses have been shown to be increased in the corpus cavernosum from rats after 
cavernous nerve injury and in cavernosal tissues from men with post-prostatectomy ED [40].
Recent animal studies have elucidated the role of adrenergic function on the contractile 
dynamics of cavernosal smooth muscle [41]. After bilateral crush injury to the cavernosal 
nerves rats were administered phentolamine (non-selective alpha-blocker), silodosin (α1A-
selective alpha-blocker), or tap water only for 4 weeks and intracavernosal pressure (ICP) 
was monitored after (1) electrical stimulation of the cavernosal nerve proximal to the region 
of injury and (2) IV administration of tadalafil (phosphodiesterase 5 inhibitor). A significantly 
greater increase in ICP was observed for the silodosin group compared to the phentolamine 
or tap water groups after both electrical stimulation alone and co-administration with IV 
tadalafil. These findings suggest therapeutic benefit to alpha blockade for recovery of erectile 
function after RP. The authors translated their experiments to humans by obtaining strips of 
cavernosal smooth muscle at the time of inflatable penile prosthesis insertion. The response 
to electrical stimulation ex-vivo was enhanced by pretreatment of the muscle strips with both 
silodosin and tadalafil compared to tadalafil alone (Figure 4) [41].
4. Epidemiology of erectile dysfunction
The prevalence of erectile dysfunction in the general population has been reported by two 
large surveys: the Massachusetts Male Aging Study (MMAS) and the National Health and 
Figure 4. Effects of tadalafil, silodosin, or their combination on neurogenic relaxations induced by electrical field 
stimulation in human corpus cavernosum strips obtained from patients with erectile dysfunction after RP (ED-RP). 
*P < 0.05, *** P < 0.001. Reprinted from Martinez-Salamanca et al. [41].
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Social Life Survey (NHSLS). According to the MMAS the rate of complete, moderate, and 
mild ED for the study of n = 1709 community-dwelling men in their 40–70 seconds was 5.1–15, 
17–34, and 17%, respectively [42]. The NHSLS examined n = 1410 community-dwelling men 
and women in 1992 and reported rates of ED by age: 7%, 18–29 years; 9% 30–39 years; 11% 
40–49 years; 18%, 50–59 years [43]. The definition of ED in this study was not quantified with 
validated questionnaires. International studies have reported rates of 20–40% for men 60–69 
years [44]. ED is therefore an age-dependent disease. Other established risk factors include 
diabetes mellitus, hypertension, hyperlipidemia, psychiatric/psychologic disorders, history 
of pelvic trauma, chronic disease states (i.e. hypogonadism, thyroid disease, chronic kidney 
disease), and socio-demographic status.
There are multiple validated questionnaires to accurately assess various aspects of a patient’s 
baseline sexual function. These questionnaires are integral in the patient workup as both a 
quantifiable measure of their function and a method of realistic prognostication of their likeli-
hood of meaningful recovery. These elements comprise an important aspect of patient preop-
erative counseling and informed consent. The International Index of Erectile Function (IIEF) 
consists of 15 items and five domains and was developed by an international panel of experts 
for uses in determining treatment efficacy in clinical trials [45, 46]. Given its high sensitivity 
for detecting clinically significant treatment effects, it is regarded as the gold standard treat-
ment outcome measure. Administration of this long questionnaire is somewhat cumbersome 
in a routine clinic setting, however. The National Institutes of Health’s Consensus Panel on 
ED lead the development of an abridged five-item version of the IIEF, called the IIEF-5 or 
the Sexual Health Inventory for Men (SHIM). The SHIM is a powerful grading system and 
easily-administered patient reported tool [47]. It has high sensitivity and specificity and has 
been shown to be more reliable than a single item self-assessment of severity of ED [48]. Each 
question is rated on a Likert scale from 1 to 5, and consists of: “Over the past 6 months”:
1. How do you rate your confidence that you could get and keep an erection?
2. When you had erections with sexual stimulation, how often were your erections hard 
enough for penetration (entering your partner)?
3. During sexual intercourse, how often were you able to maintain your erection after you 
had penetrated (entered) your partner?
4. During sexual intercourse, how difficult was it to maintain your erection to completion of 
intercourse?
5. When you attempted sexual intercourse, how often was it satisfactory for you?
Based on response to the questions, men may be categorized into one of five grades of ED 
severity: no ED (SHIM 22–25), mild (17–21), mild to moderate (12–16), moderate (8–11), 
severe (1–7). Although there have been multiple other questionnaires published—the Quality 
of Erection Questionnaire, the Erectile Dysfunction Inventory of Treatment Satisfaction 
(EDITS), the Self-Esteem and Relationship questionnaire (SEAR); the Erection Hardness 
Score (EHS), the Sexual Experience Questionnaire—the IIEF and SHIM are the most widely 
employed, and have indeed been translated into over 30 languages [49, 50]. Another popular 
health-related quality of life (HRQoL) questionnaire specific to prostatectomy patients is the 
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Expanded Prostate Cancer Index Composite (EPIC), which examines urinary, bowel, sexual, 
and hormonal domains [51]. Some of these validated instruments have been used to measure 
outcomes in the randomized penile rehabilitation studies (see below).
Studies of ED prevalence among men prior to undergoing radical prostatectomy report 
potency rates ranging from 43 to 84%; the 43% value was obtained through interrogation with 
the IIEF [52–54]. The landmark prospective Prostate Cancer Outcomes Study (PCOS) included 
n = 3533 men from the Surveillance, Epidemiology and End Results (SEER) cancer registries 
diagnosed with prostate cancer in 1994–1995. A total of n = 1288 men who underwent radical 
prostatectomy had completed a baseline questionnaire were included. Baseline erections firm 
enough for intercourse was 81%, with 49% reporting a least “little/some” difficulty in main-
taining erections [52, 53]. A limitation of these figures, however, is the fact the FDA approval 
of sildenafil only occurred in 1998 and “baseline” function was assessed through post-hoc 
recall within 6 months after treatment in 90% of patients, thereby introducing recall bias.
4.1. Incidence of erectile dysfunction after radical prostatectomy
Recovery rates after bilateral nerve-sparing open RRP ranges from 31 to 86% of sexually 
active men with organ-confined disease [55]. The recovery rates for unilateral nerve-sparing 
range from 13 to 56%, and for non-nerve sparing 0–17% [56–60]. The CaPSURE database of 
community-based Urology practices has reported that only 20% of men return to preopera-
tive baseline potency at 12 months after RP [61]. The metric for assessment has an impact on 
the incidence of ED, and the use of validated questionnaires such as the IIEF tends to expose 
higher incidence of ED [55]. The long-term outcomes of the PCOS study demonstrated [53] 
worse erectile function in men after RP compared to radiation therapy at the 2- and 5-year 
evaluation time points, odds ratio 3.46 and 1.96, respectively. There was no significant differ-
ence at the 15-year follow-up time point, however. Defining sexual function as “erections in 
sufficient for intercourse” produced absolute rates of ED at 2, 5, and 15 years of 78.8, 75.7, and 
87%, respectively (Figure 5). Of note, only 14.5% of men underwent bilateral nerve-sparing 
surgery in this series.. Among men who had bilateral nerve-sparing, 5-year erectile function 
firm enough for intercourse was reported in 40% of men vs. 23% and 23% for unilateral nerve-
sparing and no nerve-sparing, respectively. Age was a significant predictor on multivariable 
analysis. Some limitations were the late approval of sildenafil in 1998 and the fact that RP was 
performed in an open manner, which limits applications to modern series. During the 3 years 
prior to the 5 year evaluation, only 43% of men had tried sildenafil.
Contemporary robotic prostatectomy series demonstrate 12 month potency rates ranging 
from 70 to 80% [62]. A systematic review and meta-analysis of 15 case series totaling n = 3491 
patients reported 12- and 24-month potency rates ranging from 54–90% to 63–94%, respec-
tively [63]. Among patients who had bilateral nerve-sparing, 12- and 24-month potency rates 
were 74 and 82% respectively. There may be a learning-curve effect with the robotic prosta-
tectomy outcomes as well. The impact of surgeon experience/learning has been reported, but 
did not demonstrate statistical significance for potency rates between cases 1–300, 301–500, 
and 501–700 (61, 63, 65%, respectively) [64].
Outcomes stratified by specific nerve-sparing approach are presented below (see Section 5.3 
below).
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4.2. Prognostic factors for recovery of erectile function post-prostatectomy
Factors for successful recovery of erectile function have been examined for patients after both 
open radical retropubic prostatectomy (RRP) and robotic prostatectomy in the modern era. 
A systematic review post-RRP identified age <60 years, completeness of nerve-sparing, and 
pre-operative sexual function [55]. Indeed, in the PCOS study a significantly higher propor-
tion of men <60 years reported satisfactory response to sildenafil compared to older men 
(p = 0.01) [52]. The systematic review of robotic prostatectomy by Ficarra et al. cited age, 
baseline potency status, comorbidities index, and extent of nerve-sparing as predictors of 
postoperative recovery of potency [63]. There may be a learning-curve effect with the robotic 
prostatectomy outcomes as well. As discussed below, since nerve-sparing may be performed 
in an incremental manner rather than an “all-or-none” phenomenon, grade of nerve sparing 
has shown an influence on recovery [12, 65, 66] (see Techniques of Nerve Sparing below).
The impact of surgeon experience/learning has been reported [67], but did not demonstrate 
statistical significance for potency rates between cases 1–300, 301–500, and 501–700 (61, 63, 
65%, respectively) [64]. As mentioned previously, lack of electrocautery during neurovascular 
bundle dissection portends earlier recovery of erectile function [31]. While other factors have 
been cited, the previous predictors are the most consistent throughout the medical literature.
Post-operative potency rates may be influenced by the time point of assessment. Studies typi-
cally report 12 and 24 month outcomes as the longest follow-up. Although recovery typically 
occurs within the first 2 years after surgery, delayed recovery is also possible. A series of 
n = 1003 men who underwent either open or robotic RP between 2007 and 2013 reported on 
the achievement of “good erectile function” as defined by IIEF-6 score ≥ 22 [68]. Among men 
with poor function at 12 months, the probability of recovering erectile function at 24, 36, and 
48 months was 22, 32, and 40% on Kaplan–Meier analysis. The 12-month functional score and 
patient age were the only significant predictors of delayed recovery on multivariable analysis. 
Figure 5. Sexual function over 15 years after treatment for prostate cancer. A. In all patients. B. Higher sexual function 
with International Index of Erectile Function (IIEF) score > or = 80; C. Lower sexual function, IIEF < 80. Numbers represent 
total of patients in radical prostatectomy (RP) group/radiation group. Reprinted from Resnick et al. [53].
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Also, very interestingly, the degree of nerve-sparing was not a predictor of delayed recov-
ery; perhaps nerve-sparing only impacts early recovery at the 12-month time point. Surgical 
modality (open vs. robotic) was not explored. Similar findings of delayed recovery have been 
published in other reports [69, 70]. Such findings may be tempered by the gradual decline in 
erectile function after year 5 observed in the Prostate Cancer Outcomes Study [52].
5. Methods to improve nerve-sparing
5.1. Preoperative planning with multi-parametric MRI
Multiparametric magnetic resonance imaging (mpMRI) has gained widespread use in the 
workup of elevated PSA and diagnosis of prostate cancer via MRI-transrectal ultrasound 
(TRUS) targeted fusion biopsy. This technique has been shown to increase the detection rate 
of high-grade (i.e. Gleason 4 + 3 = 7) prostate cancer by 30% and result in lower detection 
of low grade prostate cancers by 17% [71]. The recently published PROMIS trial evaluated 
the performance of mpMRI to the reference standard template prostate mapping (TPM) 
biopsy and reported superior sensitivity for mpMRI compared to TRUS biopsy (93% vs. 48%, 
p < 0.001) and negative predictive value (89% vs. 74%, p < 0.001), allowing 24% with negative 
MRI to safely avoid having to undergo biopsy [72].
The utility of MRI may be applied to the domain of pre-surgical planning as well. The aggres-
siveness of nerve-sparing is not solely based on surgeon experience, but also on the anatomical 
location of the tumor and the presence of locally advanced (i.e. pT3a-b) disease that may be 
invading the neurovascular bundle. In the setting of pT3 disease (i.e. extraprostatic extension 
(EPE) and seminal vesicle invasion (SVI)), aggressive nerve sparing may result in a positive 
surgical margin (PSM), which has been associated with increased rates of biochemical recur-
rence, systemic metastasis, and prostate cancer-specific mortality post-prostatectomy, espe-
cially for high grade disease (i.e. Gleason Score 8–10) [73]. Even with careful adherence to 
surgical technique and the use of intraoperative frozen section analysis, microscopic positive 
margins may be imperceptible during surgery. A meta-analysis of 75 studies comprising 9796 
patients who underwent mpMRI between 2000 and 2015 demonstrated high specificity for the 
detection of EPE (90%) and SVI (95%) [74]. However, sensitivity for these endpoints in the best 
performing series was 71–73%. Therefore, mpMRI may be limited in detecting microscopic 
EPE and SVI, which surely impacts the safety of nerve-sparing, especially in high risk patients.
Despite these limitations, there is level one evidence published by a single center in Norway 
suggesting that preoperative mpMRI does indeed reduce the rate of positive surgical margins 
at robotic radical prostatectomy and influences the rate of nerve-sparing in patients who oth-
erwise might not have been considered for a nerve-sparing approach [75]. Among the n = 438 
men randomized in this study to preoperative MRI vs. no MRI, sensitivity and specificity for 
detection of pT3 disease was 73 and 65%, respectively. The mpMRI information altered surgi-
cal approach in 27% of patients. Bilateral nerve sparing was performed 6.7% less frequently 
in the mpMRI group. The positive margin rate was reduced in the mpMRI group for cT1c 
patients (16% vs. 27%, p = 0.035). Among the patients found to have pT3 disease, 89% of them 
had only unilateral nerve sparing or no nerve sparing. This group did not have improvement 
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in positive margin rate with the mpMRI, however. Perhaps, even wider excision is required 
to render these patients free of positive margins, which has implications for post-operative 
potency. Further study is surely needed to clarify the role of mpMRI for pre-surgical planning.
5.2. Intraoperative nerve-sparing techniques
Refined understanding of the neuroanatomy of the cavernous nerves informs the surgical 
approach to and completeness of nerve-sparing. The endopelvic fascia is a multilayered 
sheath that encloses and buttresses the prostate and bladder and attaches these organs to 
the pubic bone via the puboprostatic ligaments. This fascia fuses as the arcus tendineus fas-
cia pelvis just lateral to these organs. The fascial investments of the prostate may be further 
divided into the prostatic “capsule,” periprostatic veins with their fascia, the lateral pelvic fas-
cia (prostatic fascia), levator fascia, and levator ani muscles (Figure 6) [76]. Lepor and Walsh 
described nerve sparing in 1983, with the approach beginning at the prostate apex and pro-
ceeding in a retrograde fashion toward the prostatic vascular pedicle [6, 7]. In the modern era 
of minimally invasive and robotic techniques, the nerve-sparing is usually performed in an 
antegrade manner after first controlling the prostatic vascular pedicle. Initial experiences with 
robotic prostatectomy employed monopolar or bipolar electrocautery to control the pedicle 
until the detrimental role of thermal injury was fully appreciated.
Classical approaches to nerve-sparing have been described as “interfascial” vs. “intrafascial” tech-
niques, as well as the “extra-fascial” approach when nerve-sparing is not performed (Figure 7). 
Interfascial dissection follows the plane lateral to the prostatic fascia, which may render the NVB 
prone to partial resection. The intrafascial technique follows the plane directly on the prostatic 
capsule, medial to the prostatic fascia and anterior to the Denonvilliers’ fascia, especially at the 
5:00 and 7:00 positions. Dissection is typically performed with both blunt and sharp dissection in 
an athermal manner to reduce transmission of heat and electricity to the proximal NVB.
Refinements in the understanding of the neuroanatomy have resulted in more sophisticated 
classifications of nerve-sparing. An important concept is the ability to perform incremental 
nerve sparing, not just as an “all-or-none” phenomenon. It has been suggested that optical 
magnification and the extended degree of freedom afforded by robotic surgery facilitates 
Figure 6. Planes for dissection of nerve-sparing based on prostatic fascial layers. LPF = lateral pelvic fascia (prostatic 
fascia); LF = levator fascia; LA = levator ani. Reprinted from Tewari et al. [76].
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Figure 7. Intrafascial, Interfascial, Extrafascial dissection planes as the basis for nerve-sparing. VEF ant.-lat. = visceral 
endopelvic fascia anterior-lateral; PEF = parietal endopelvic fascia; C = capsule of prostate; LAF post.-lat. = levator ani 
fascia posterior-lateral; PF = prostatic fascia. Reprinted from Walz et al. [9].
development of dissection planes within the NVB itself to perform partial nerve sparing in the 
setting of concern for pT3 disease [12, 77]. This concept is illustrated in Figure 6. Dr. Tewari’s 
series of n = 2317 patients was published in 2011 [76]. This approach relies on a risk-stratified 
approach to the “neural-hammock” as defined by the periprostatic veins and based on preop-
erative risk stratification based on Gleason score, PSA, digital rectal examination (DRE) find-
ings, cancer volume, and mpMRI findings. The plane of dissection follows one of the grades 
illustrated in Figure 6. A similar grading system based on periprostatic arterial anatomy, rather 
than venous anatomy, has been proposed by Schatloff et al. (Figure 8). In their smaller series 
of n = 132 patients, they cite a landmark periprostatic artery to define grades as: 1, no nerve 
sparing; 2, <50% nerve-sparing; 3, 50% nerve sparing; 4, 75% nerve-sparing; 5, ≥95% nerve 
sparing [78]. The Menon et al. series reported on n = 2652 patients for whom nerve-sparing 
was initiated by incising the prostatic fascia anteriorly, termed “high anterior release” or the 
“Veil of Aphrodite” technique (Figure 9) [79]. The authors originally reported the develop-
ment of a plane between the prostatic capsule and prostatic fascia cranially at the base of the 
seminal vesicles. This plane is propagated deep to the periprostatic venous sinuses with careful 
blunt and sharp dissection. For patients with significant periprostatic fibrosis after biopsy that 
impairs development of this plane, the authors recommend initiation of the dissection at the 
2:00 or 10:00 position [79].
5.3. Outcomes of nerve-sparing techniques
Comparison of potency rates after the various surgical techniques is not straightforward, 
as there may be differences in patient demographics such as age and baseline potency, 
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as well as tumor characteristics such as stage and grade that may influence the ability to 
perform bilateral nerve-sparing. Furthermore, based on the aforementioned variations in 
neuroanatomy among different patients, perfect execution of a given surgical technique 
may not be enough to accommodate a particular patient’s anatomy, resulting in the vari-
ability of erectile function recovery. Definitions of potency also vary, with some studies 
reporting percentage return at a given time point or “return to baseline.” The most robust 
series employ the validated questionnaires (IIEF, SHIM, EPIC), but precise cut-offs for res-
toration of function may vary. To add the possibility of subjective satisfaction beyond the 
numbers of the questionnaires, some studies also define potency as “erections suitable for 
intercourse” that are “satisfactory.”
In the setting of these limitations, a recent systematic review and meta-analysis of six studies 
(only one randomized and three prospective; 4/6 minimally invasive approach) of n = 1663 
Figure 8. Grades of nerve-sparing based on anatomic landmark of periprostatic artery. LA = landmark artery. Reprinted 
from Schatloff et al. [78].
Figure 9. Plane of dissection for Veil of Aphrodite nerve-sparing technique. Reprinted from Menon et al. [79].
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patients reported improved erectile function at 6 months (RR 1.49) and 12 months (RR 1.40) 
for intrafascial vs. interfascial nerve-sparing.
Erectile function is not the only component of the Trifecta directly affected by nerve-spar-
ing. Oncologic control with regard to the presence of positive surgical margins is also very 
important. Given the increased rates of biochemical recurrence and possibility of increased 
rates of metastasis and prostate-cancer specific mortality associated with the presence of a 
positive surgical margin, nerve-sparing outcomes must be understood within the context of 
margin status. Overall, the rates of PSM are around 15%, with rates ranging from 6 to 38% and 
influenced by pathologic stage, grade, and D’Amico risk category [80]. There have also been 
reports that bilateral vs. unilateral nerve-sparing in the setting of pT2 disease is associated 
with a higher rate of PSM, as demonstrated in a series of n = 9915 patients who underwent 
robotic prostatectomy at two institutions, with relative risk 1.52 [81]. Other studies have not 
corroborated an increased positive margin rate for intrafascial vs. interfascial nerve-sparing 
techniques (rate of 9% vs. 9.5%) [82]. The grades of nerve-sparing proposed by Dr. Tewari 
have been associated with excellent PSM rates, likely owing to preoperative risk stratifica-
tion based on Gleason score, PSA, digital rectal examination (DRE) findings, cancer volume, 
and mpMRI findings. The rates of PSM for patients with nerve-sparing grades 1, 2, 3, and 4 
were 9.9, 8.1, 7.2, and 8.7%, respectively (p = 0.636). The Schatloff series also reported their 
PSM rate, which was 9% overall. Although the rate of PSM for grade 1 NS was 0%, there was 
otherwise no consistent correlation between grade of NS and PSM rate (0, 5.7, 16.7, 7.5, 3.6% 
for grades 1, 2, 3, 4, and 5, respectively), perhaps reflecting good presurgical planning based 
on patient risk factors [78]. The Veil of Aphrodite technique by the Vattikuti Urology Institute 
reported a positive margin rate of 13%, which declined to 1.5% for pT2 disease after modifica-
tion of approach to include en face oversewing of the DVC after apical transection [79].
Regarding the potency rates, it is necessary to standardize the definition of potency, which 
usually incorporates routine use of oral PDE 5 inhibitors. Furthermore, there is a distinction 
between restoration of penetrative sexual intercourse vs. return to baseline functioning. There 
are several contemporary series reporting erectile function outcomes after robotic prostatec-
tomy. Tewari’s risk-stratified approach to neural-hammock sparing in n = 2317 men resulted 
successful intercourse (score of ≥4 on question two of the SHIM and total SHIM >21) of 90.9, 
81.4, 73.5, and 62% for nerve-sparing grades 1, 2, 3, and 4, respectively [76]. Regarding return 
to baseline function: grade 1, 81.7%; grade 2, 74.3%; grade 3, 66.1%; grade 4, 54.5%. Of note, 
this group also reported earlier return of continence associated with the higher grades of 
nerve-sparing, which has been controversial [83]. Incidentally, a recent systematic review and 
meta-analysis of 27 longitudinal cohort studies totaling n = 13,749 patients, however, reported 
that early urinary continence (at 6 months post-RP) was improved for patients undergoing 
nerve-sparing vs. non-nerve-sparing surgery (88.9% vs. 69.8%) [84].
Tewari’s technical modification of adding real-time penile oxygen monitoring demonstrated 
that at 6 weeks postoperatively, a larger proportion of patients in the O
2
 monitoring group 
had no ED (24.5% vs. 10.4%, p < 0.05) and at 52 weeks this difference was persistent (84% vs. 
68%, p < 0.05). Furthermore, using the Sexual Health Inventory for Men (SHIM) validated 
questionnaire at 1 year, a greater number proportion of patients reported minimal to no ED 
(94% vs. 78%, p < 0.05). In this report, the authors did not sub-stratify by grade of nerve spar-
ing [85] (see Section 5.4).
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The Schatloff series on grade stratification based on periprostatic arterial anatomy did not 
report functional outcomes [78]. The Vattikuti Institute series included n = 1142 patients with 
minimum follow-up of 12 months and among men with normal preoperative function (i.e. 
SHIM >21) potency rates were 68% in the standard bilateral nerve-sparing patients and 93% 
in the bilateral Veil nerve-sparing patients [79]. Return to baseline rates depended on pre-
operative function, and for those without preoperative dysfunction, return to baseline was 
39% for standard nerve-sparing and 73% for the Veil technique. Despite these very favorable 
results, the authors disclosed that only 50% of these patients attained normal SHIM score 
without medication. Although these findings suggest that the Veil offers improvements in 
recovery of erectile function, there may be a bias of surgeon experience, as the Veil technique 
was employed later in the learning curve of this single-surgeon series. This series also dem-
onstrated 84% total urinary control, and 95% social continence (one pad or liner per day) at 
12 months follow-up. The role of nerve-sparing in earlier recovery of continence has been 
corroborated by many series [86–88].
Some limitations of these studies are that they are single institution and often single-surgeon 
series and there is no direct comparison among different techniques to be able to assess supe-
riority. Furthermore, there may be shortcomings with translation of these techniques into 
the larger urologic community compared to the immensely high-volume centers where these 
techniques were invented.
5.4. Intraoperative penile oxygen monitoring
The real-time impact of neurovascular bundle tension on cavernosal ischemia was investi-
gated by Tewari et al. in n = 64 patients [85]. During robotic prostatectomy, these patients 
underwent real-time penile oxygen monitoring with the Odissey Tissue Oximeter probe 
placed 2 cm from the base of the penis. Surgical dissection was altered whenever the O
2
 alarm 
sounded until oxygenation was restored to 85%. Functional outcomes were compared to a 
propensity-matched historical control group of n = 192 patients (matched for age, preopera-
tive prostate specific antigen (PSA), baseline erectile function, comorbidity status, and extent 
of nerve-sparing). Steps in the operation associated with significant decline in tissue oxygen-
ation included opening the endopelvic fascia, all of the nerve-sparing, excessive traction on 
the Foley catheter, seminal vesicles, or prostate during the apical dissection, and control of the 
dorsal vein complex (DVC) prior to apical dissection. Of note, control of the DVC if done after 
apical transection was not associated with significant penile ischemia. At 6 weeks postopera-
tively, a larger proportion of patients in the O
2
 monitoring group had no ED (24.5% vs. 10.4%, 
p < 0.05) and at 52 weeks this difference was persistent (84% vs. 68%, p < 0.05). Furthermore, 
using the Sexual Health Inventory for Men (SHIM) validated questionnaire at 1 year, a greater 
number proportion of patients reported minimal to no ED (94% vs. 78%, p < 0.05). These find-
ings provide clinical evidence for the importance of minimizing neurovascular bundle manip-
ulation during robotic prostatectomy as a means of preventing neurapraxia/axonotmesis.
Similar evidence comes from a well-designed prospective, randomized, single-blinded study 
of n = 61 with normal preoperative erectile function from 6 centers [89]. Patients underwent 
robotic prostatectomy with traditional bilateral nerve sparing compared to nerve-sparing 
using the Cavermap Surgical Aid. A 12 months post-op, the Cavermap group had mean 
15.9 minutes of greater than 60% nocturnal tumescence vs. 2.1 minutes as measured by the 
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RigiScan. The sexual function inventory questionnaire (SFIQ) scores at 12 months were not 
significantly different, however. Among those patients with intact response to nerve stimu-
lation after nerve-sparing, 68% of those with bilateral response had recovery on SFIQ vs. 
27% with unilateral response, and 0% with no response [89]. A subsequent multi-institutional 
study utilizing the Cavermap by five experienced surgeons demonstrated limited specificity 
to identify the precise location of the cavernous nerves, thus limiting its routine application 
during radical prostatectomy [90].
5.5. No countertraction technique
The detrimental impact of nerve traction injury may also be limited. A series emphasizing 
nerve-sparing with a lack of countertraction has been published (Figure 10). Kowalcyzk et al. 
reported statistical significantly different erectile function at 5 months post-robotic prostatec-
tomy (24.9% vs. 18.4%, p = 0.004), which was confirmed in the multivariable regression model. 
These differences were no longer present at 12 months (34.7% vs. 33.5%, p = 0.849), indepen-
dent of preoperative erectile function, laterality of nerve sparing, and inter- vs. intrafascial 
approach [91]. Therefore, “tractionless” surgery may accelerate functional return.
5.6. Minimizing use of electrocautery/thermal energy
In the early experience of robotic prostatectomy, many centers performed dissection of the 
neurovascular bundle with electrocautery. Ahlering et al. demonstrated slower return of erec-
tion function as measured by the IIEF-5 and two questions on the EPIC questionnaire. Of the 
n = 125 patients, only 36 met their inclusion criteria, (age < 66 and IIEF-5 score 22–25), with n = 3 
having had monopolar electrocautery and n = 33 having had bipolar cautery. Of note men with 
Gleason 7–10 and high volume disease had ipsilateral wide excision of the NVB. Although 
there was no comparison group, erectile function recovery was modest especially when com-
pared to modern historical series. Among those who had bilateral nerve-sparing, recovery at 
15 months was 44.4% and at 24 months was 67.9% [31]. These findings help to support the clini-
cal principle of avoidance of thermal energy during dissection of the neurovascular bundle.
Figure 10. Technique of nerve-sparing with assistant suction neurovascular bundle countertraction which is avoided in 
the Kowalcyzk et al. technique of nerve-sparing. Reprinted from Kowalczyk et al. [91].
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5.7. Seminal vesicle preservation
Building on several observational studies [92, 93], Gilbert et al. reported a randomized con-
trolled, Phase II trial of n = 140 men who underwent radical prostatectomy [94]. Seminal 
vesicle-sparing approach was employed in 71 men. At 6 and 12 months post-operatively, 
sexual and urinary function scores were similar on the EPIC questionnaire (erections firm 
enough for intercourse in 67.7% vs. 56.3%, p = 1). In addition, positive surgical margin status 
and 12-month biochemical recurrence rates were similar. This approach has understandably 
not been widely adopted.
5.8. Hypothermic robotic radical prostatectomy
Finley et al. reported the potential benefit of regional hypothermia/cold dissection of the neu-
rovascular bundle in a case–control study of n = 115 who underwent robotic prostatectomy 
[95, 96]. The rationale for the endeavor mirrors developments in neurosurgery and cardiac surgery 
that have established significant benefits in randomized studies. Hypothermia was employed to 
minimize iatrogenic tissue inflammation and consequent cellular edema, lactic acidosis, nerve 
conduction blockade, free radical damage, and apoptosis that characterizes damage to muscle 
and nervous tissue. Cold intracorporeal irrigation was employed along with an endorectal 
cooling balloon cycled with saline at 4°C. Potency rates at 12-months were favorable. Patients 
subjected to hypothermia were compared to a historical cohort of n = 667 patients. Temperature 
probes monitored the endorectal and intracorporeal temperatures, which declined to mean 18.7 
and 25.6°C, respectively. Potency was assessed during validated questionnaires and defined as 
“erections adequate for penetration” and “were the erections satisfactory.” Potency at 3 months 
was similar, but at 15 months, the hypothermic group had significantly better function (83% vs. 
66%, p = 0.045). There were no differences in oncologic outcomes and no complications related 
to the technology [97]. These results need further multi-institutional investigation.
5.9. Clipless antegrade nerve preservation
Rather than perform the nerve-sparing in the conventional antegrade (base to apex) fashion, 
some centers have described a medial to lateral approach. After division of the posterior blad-
der neck, the posterior plane along the prostate is developed toward the prostatic apex in the 
midline. The dissection proceeded laterally to release the vascular pedicles and neurovascular 
bundles in a medial to lateral direction, with sparing use of bipolar cautery. No monopolar 
cautery or clips were used. Chien et al. reported their series of n = 56 patients who underwent 
robotic prostatectomy using this approach between 2003 and 2004 [97]. Their outcome metrics 
relied on the Rand Medical Outcomes Study 36-Item Health Survey, version 2, as well as the 
University of California, Los Angeles, Prostate Cancer Index up to 12 months postop. Return 
to baseline potency (allowed use of oral phosphodiesterase inhibitors) among patients with 
bilateral nerve-sparing occurred in 69%. The positive surgical margin rate in this series was 
similar to other published techniques at 10.7% [97].
5.10. Intraoperative frozen section analysis
There have been multiple reports of the utility of intraoperative frozen section to allow for 
more aggressive nerve-sparing in patients whose risk factors may have otherwise prompted 
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a non-nerve sparing surgical approach. In an open series of n = 608 patients who underwent 
RP, 83 patients were found to have a palpable lesion close to the prostatic capsule [98]. A 4 cm 
wedge of tissue was excised in the suspicious area for intraoperative frozen section (IOFS). 
A total of 93% of these IOFS were positive for carcinoma, and 36% of these were pT3. Final 
positive margin rate overall was 16%. This real-time decision-making allowed for ipsilateral 
nerve-sparing in 52% of the cases without a negative impact on PSM. Of note, there was a false 
positive PSM rate of 17%. The applicability to the modern era of robotic prostatectomy may not 
be lost, but would be based on gross visual suspicion of tumor violation during nerve-sparing.
Another center has pioneered the Neurovascular Structure-Adjacent Frozen-section Examination 
(“NeuroSAFE”) approach to nerve sparing [99]. In this technique, a bilateral nerve-sparing 
procedure is performed and then the prostate gland is promptly extracted from the surgical 
field and whole gland circumferential frozen section analysis is performed. The original series 
consisted of n = 11,069 who underwent open RRP from 2002 to 2011, n = 5392 of whom had the 
NeuroSAFE technique. When a margin was found to be positive, the ipsilateral neurovascular 
bundle was resected, including the rectolateral component of the Denonvilliers’ fascia, prior to 
the vesicourethral anastomosis. The sensitivity and specificity of this approach was 93.5 and 
98.8%, respectively, with accuracy of 97.3%. Of the 25% found to have PSM initially, 85% of 
these were converted to final negative margin. False negatives occurred in 2.5% and all of these 
margins were < 0.5 mm. There were significant reductions in PSM rates within each pathologic 
tumor stage (except for pT3b) and an increase in the rate of nerve-sparing for all stages. Of note 
processing time took about 35 minutes and there was no delay in surgery, as hemostasis, blad-
der closure, lymph node dissection, and posterior reconstruction could be performed during 
this time (Figure 11) [99].
This technique has been translated into robotic surgery in n = 1570 patients from 2004 to 2012, 
in whom n = 1178 had the NeuroSAFE technique. Intraoperative blood loss was equivalent 
and nerve-sparing rate increased significantly (overall 97% vs. 81%; pT2 99% vs. 90%; pT3a 
94% vs. 74%; pT3b 91% vs. 30%). Furthermore, rate of PSM improved with NeuroSAFE (over-
all 16% vs. 24%; pT2 8% vs. 15%; pT3a 22% vs. 39%; pT3b 49% vs. 67%; p < 0.05) [100]. These 
findings have contributed to the development of the “Safe-R score,” a composite measure of 
margin status and laterality of nerve sparing [101].
5.11. The influence of surgical modality on nerve-sparing success
It has been postulated that the loss of haptic feedback renders traction-free nerve-sparing diffi-
cult during robotic prostatectomy. Conversely, the optical magnification and seven-degrees of 
freedom afforded by robotic surgery may allow for superior delineation of the neuroanatomy, 
precision of dissection, and even performance of partial or incremental nerve sparing for patients 
with concern for locally advanced disease. Such patients may have otherwise been subjected to 
a non-nerve-sparing technique. Tewari et al. reported earlier return of 50% erectile function (as 
reported on the EPIC questionnaire) after robotic prostatectomy vs. RRP (mean 180 days vs. 440 
days, p < 0.05) and earlier return to intercourse (340 days vs. >700 days, p < 0.05) Interestingly, 
these findings were shown even in the setting of a greater number of patients post-RRP using 
sildenafil (65% vs. 42%) [102]. Such findings were also corroborated by a prospective, non-
randomized trial of robotic prostatectomy vs. RRP in n = 208 patients from 2006 to 2007. At 
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12 months follow-up, of the patients with bilateral nerve-sparing, those who underwent the 
robotic procedure had superior recovery of erectile function on the IIEF-5 questionnaire (81% 
vs. 49%, p < 0.001) [62]. Further contemporary evidence comes from a systematic review and 
meta-analysis of 31 studies published between 2008 and 2011 totaling n = 3491 patients [63]. 
Outcome measures of erectile function were heterogeneous, with some studies employing 
SHIM > 21 and others using “erections sufficient for intercourse.” Cumulative analyses of the 
six studies with suitable follow-up demonstrated better 12-month potency rates after robotic 
surgery vs. RRP (24.2% vs. 47.8%; odds ratio 2.84, p = 0.002). Absolute risk reduction was 23.6%. 
Furthermore, 24-month potency was 84% vs. 47% (odds ratio 6.01; p < 0.001) Comparison 
between robotic and laparoscopic approaches was not significant (39.8% vs. 55.6%, p = 0.21).
These comparisons may be hampered by different definitions and metrics for erectile dys-
function, patient selection for surgery, and variations in post-operative penile rehabilitation 
at different institutions. Further evidence is forthcoming from the first randomized con-
trolled phase 3 study of robotic vs. open prostatectomy conducted by Yaxley et al. out of 
Australia [103]. Although the study randomized n = 326 men and plans to report on urinary 
Figure 11. A. Intraoperative picture of NeuroSAFE technique. B. Intraoperative frozen section with tumor contact at 
linked surface. Reprinted from Beyer et al. [100].
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and sexual function outcomes (via the EPIC and IIEF questionnaires) at 6 and 12 weeks, as 
well as 24 months, published results are immature at 12 weeks only. There were no signifi-
cantly different urinary or sexual function scores at 6 and 12 weeks, nor were there differ-
ences in health reported quality of life.
A counterargument to the benefits afford by robotic surgery, however, states that more aggres-
sive nerve sparing, although technically feasible, may not be oncologically safe, given the risk of 
positive margins. Indeed, the Preston et al. study revealed that positive margins were more likely 
in patients treated with robotic surgery (relative risk 1.76) compared to open surgery, while there 
was no difference between lap and robotic surgery [81]. These findings were not corroborated in 
a very large, albeit retrospective, multi-institutional, multi-national study of n = 22,393 patients, 
however, which found the lowest rate of positive margins in robotic prostatectomy (13.8%) vs. 
laparoscopic (16.3%) vs. open (22.8%) [104]. A recent systematic review and meta-analysis by 
Novara et al. of 21 studies totaling n = 19,238 patients reported similar PSM rates among robotic, 
laparoscopic, and open surgery, both overall and when sub-stratified into pT2 patients (mean 
15%, range 6.5–32% [105]. More recent evidence to mitigate this controversy comes from the 
previously referenced randomized Phase 3 trial of open vs. robotic prostatectomy by Yaxley 
et al. Oncologic outcome were equivalent between the two groups, including PSM overall, and 
for pT2 and pT3 patients (15% vs. 10%, 3% vs. 2%, 11% vs. 8%, respectively) [103].
One notable difference between the open and robotic approach is the use of a retrograde vs. 
antegrade approach to the dissection of the neurovascular bundle. There is a theoretically 
reduced risk of placing a clip across the neurovascular bundle with the retrograde approach, 
which releases the bundle from the prostate prior to obtaining vascular control [106]. These 
different approaches were compared in a propensity-matched series of n = 344 patients under-
going robotic prostatectomy. Using validated questionnaires at 3,6, and 9 months, the potency 
rate was significantly higher after the retrograde approach (92.9% vs. 72.1% at 9 months), and 
this finding was maintained with multivariable analysis. Of note, the PSM rate was similar 
between groups (11.6% vs. 7%, p > 0.05) [107]. Of note, this was a single-surgeon series and the 
approaches were performed in an interfascial manner, which may not reflect the most current 
understanding of the cavernous neuroanatomy. Also, the retrograde approach was generally 
performed more recently in the series with possible artifactual enhancement in outcome from 
being later in the learning curve. Furthermore, the seemingly excellent results from either 
approach in this series are likely a consequence of the permissive definition of erection func-
tion (erections firm enough for penetration in >50% of attempts).
Of note, although intriguing to consider if there are any technical advantages to nerve sparing 
with an extraperitoneal vs. transperitoneal approach to robotic prostatectomy, the extant litera-
ture has thus far focused exclusively on perioperative rather than functional outcomes [108, 109].
6. Penile rehabilitation
Several options for penile rehabilitation have been proposed and investigated, including 
pharmacotherapy with oral phosphodiesterase inhibitors or penile intracavernosal injection, 
as well as use of a vacuum erection device and penile constrictive ring. Often a multimodality 
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approach is advocated. Compliance with these recommendations depends on myriad fac-
tors, including physician counseling, patient motivation, and even socioeconomic status—as 
many of the therapies are not covered under health insurance. The PCOS trial reported that 
43% of men tried sildenafil, 25% tried a vacuum erection device, and 17% tried intracavern-
ous injections [52]. Admittedly, the denominator of men who were actually offered these 
treatments is not known.
The rationale for these treatments has been investigated in preclinical models. There is indeed 
precedent for treatment success in animal models of chronic low-dose tadalafil administra-
tion, with increased cavernosal smooth muscle, decreased fibrous tissue, and functional 
enhancement of erectile function [110–112]. Similar findings have been reported for sildenafil 
after bilateral cavernosal nerve damage in a rat model. Nerve damage resulted in elevation 
in several pro-inflammatory cytokines (interleukin-1β, transforming growth factor β) and 
markers of oxidative stress (nicotinamide adenine dinucleotide phosphate [NADPH] oxidase, 
myeloperoxidase, inducible nitric oxide synthase, tumor necrosis factor receptor superfamily 
member 5 [CD40]), which then normalized after administration of sildenafil in the drinking 
water. Levels were measured by polymerase chain reaction (PCR) and proteome expression 
of pelvic ganglia neurons [113].
6.1. Mechanotherapy
The vacuum erection device often in conjunction with penile constrictive ring are routinely 
recommended for use to assist with recovery of potency after radical prostatectomy. This 
therapy not only allows for tumescence and penetration, but also cavernosal sinus expan-
sion, smooth muscle “stretching,” and mitigation of hypoxia when used on a regular basis 
[114, 115]. Compared to pharmacotherapies—which are often not covered by the patient’s 
health insurance—VED may be more cost-effective, with a decreased side effect profile and 
the opportunity for the patient and his partner to take an active role in convalescence. In 
addition, the mechanism of action does not require intact cavernous nerves for success. There 
have been multiple retrospective studies examining the impact of the VED [115–117]. These 
suggest improvement in return of spontaneous erections. In particular, a retrospective study 
of n = 203 patients who underwent robotic radical prostatectomy between 2007 and 2011 
investigated whether PD5I alone, VED alone, or a combination of the two yielded the highest 
improvement of the SHIM questionnaire, substratified into three groups of baseline EF (SHIM 
8–16, SHIM 17–21, SHIM 22–25). For each of the baseline EF groups the combination therapy 
resulted in the highest proportion of successful potency (erections suitable for penetration) 
and with the shortest latency period [118].
Randomized evidence comes from Raina et al., who reported on n = 109 patient who under-
went open RP (both NS and non-NS) randomized post-op to daily VED therapy vs. observa-
tion. Compliance with the device was 80% with 55% partner satisfaction rate. After 9 months 
of treatment IIEF-5 score was significantly increased for both the NS and non-NS patients 
compared to the no treatment group. Furthermore, decreased penile length was reported in 
63% of the control group vs. 23% among patients who responded to VED treatment [115].
Regarding timing of therapy, earlier initiation of 10 minutes daily VED therapy (1 month 
post-op vs. at 6 months) has been shown in a small randomized trial of n = 28 men to be 
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superior in terms of 1. IIEF score at 3- and 6-months, and 2. preservation of stretched penile 
length (vs. 2 cm mean decrease observed in the delayed therapy group) [119].
6.2. Pharmacotherapy
The majority of penile rehabilitation studies incorporate early post-op therapy. Phosphodies-
terase type 5 inhibitors have been demonstrated to be effective for the treatment of erectile dys-
function through their inhibitory effect on the enzyme that degrades cGMP. These medications 
augment the nitric oxide-mediation erectile response through increased relaxation of the caver-
nosal sinus smooth muscle [120]. The commercially available medications have different half-
lives of activity, with Tadalafil being the longest (T1/2 sildenafil 3–5 mg; vardenafil 4–5 hours; tadalafil 17.5 hours) [121]. There is also experience with both intraurethral and intracavernosal 
prostaglandin E, which act via a cAMP-related mechanism to effect cavernosal smooth muscle 
dilatation [122]. Montorsi et al. published the first randomized, placebo controlled trial in 1997, 
involving intracavernosal injection of alprostadil three times per week × 12 weeks beginning 
1 month after open RP [23]. Newer formulations of intracavernosal therapy include Trimix 
(prostaglandin, phentolamine—a non-selective alpha-blocker—and papaverine—a non-selec-
tive PDE5 inhibitor—and Bimix (papaverine and phentolamine). Given the invasive nature of 
ICI—as well as the putative higher complication rate regarding pain, hematoma, penile plaque 
formation, and priapism—this therapy is not universally accepted by patients. Therefore, 
there is much interest in the oral PDE5 inhibitors as a mechanism of increasing intracavernosal 
cGMP to promote smooth muscle relaxation and mitigate of the post-RP hypoxic state.
6.2.1. Oral PDE 5 inhibitors
There have been several prospective, randomized studies in this domain, which are summa-
rized Table 1. Rationale for these trials was based on findings that daily sildenafil preserves 
intracorporeal smooth muscle after radical retropubic prostatectomy [123]. The studies tended 
to exclude men with high grade prostate cancer (i.e. Gleason 8) and those who required adju-
vant radiation therapy. Latency of medication initiation is also variable, ranging from time of 
catheter removal to 4 weeks post op. Based on the cavernous neurotomy rat models in which 
post-injury cavernous smooth muscle apoptosis begins in 1 day and peaks at 1 week, earlier 
initiation of treatment has definite clinical rationale [34]. Furthermore, the study end-points 
are not identical. Some examine the impact on erections during an active treatment phase and 
others examine the rate of return of spontaneous erections (that is, without the need for phar-
macotherapy). The proportion of open vs. robotic RP are also variable (open RP: 39.7–100%). 
The Jo et al. study out of South Korea is the only study comprised exclusively of patients who 
underwent robotic prostatectomy, and showed more complete return of erectile function at 12 
months with immediate post-catheter removal initiation of 100 mg sildenafil twice weekly com-
pared to waiting until 3 months after surgery [124]. The concomitant use of VED in these studies 
is not clear, which adds another limitation to their interpretation. Also of interest is a follow-up 
study to the study by Pavlovich et al. [172] suggesting poorer EPIC scores with nightly silde-
nafil 50 mg compared to PRN dosing, largely in the urinary irritative and bother subscales of 
the questionnaire [125]. Further study is required to clarify the implications of this report.
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Author Patients Study drug Study schema F/U Outcome metric Findings Conclusion Limitations
Montorsi 
et al. [23]
30; mean age 
62, “reported 
satisfactory 
intercourse 
preop;” bilateral 
nerve-sparing
Alprostadil 
TIW × 12 
weeks
Dose titrated for 
efficacy (2–14 μg) vs. 
no injection
3 
months
“Recovery of 
spontaneous 
erections”
80% compliance with 
injections;
67% recovery vs. 20%
Early ICI with 
alprostadil 
increases 
recovery of 
spontaneous 
erections
No sham injection 
group; no IIEF 
standardized 
questionnaire; waited 
1 month short f/u; 
17% complication
Montorsi 
et al. [110]
445 (18–64 years); 
IIEF-EF ≥ 26; 
bilateral NS; mean 
age 57.1
Vardenafil × 
9 months
10 mg nightly vs. 
10 mg PRN within 2 
weeks postop
12 
months
IIEF-EF ≥ 22 after 
2-month washout; 
then open label 
PRN
Double blind period: 
IIEF > 22: 24.8, 32, 
48.2% (placebo, 
nightly, on demand);
After 2 months 
washout and open 
label PRN no 
difference
On demand 
dosing is 
effective
Did not limit 
frequency of on 
demand dosing; dose 
up to 20 mg
Padma-
Nathan 
et al. [171]
76 (18–70 years) 
s/p RRP; 8 on Q3 
and Q4 of IIEF; 
mean age 55.5
Sildenafil × 
9 months
Nightly 50 mg, 100 
mg, placebo within 
4 weeks
12 
months
IIEF after 8 
week washout; 
plethysmography
IIEF Q3 + Q4 ≥8 and 
“satisfactory”: 4, 26, 
29% (placebo, 50 mg, 
100 mg)
Sildenafil 
improved 
erectile function, 
but no dose 
dependence
Closed early for lack 
of treatment effect; 
very low rate of EF in 
placebo arm; waited 
4 weeks
Pavlovich 
et al. [172]
100 (<65 years) s/p 
MIS RP; IIEF-EF ≥ 
26, uni-/bilateral 
NS; mean age 53.9
Sildenafil × 
12 months
50 mg nightly vs. 
PRN (max 6 per 
month) immediately 
after RP
13 
months
IIEF, EPIC after 
1-mo washout
IIEF-EF > 21: 33.2, 
50% (nightly, on 
demand)
No difference in 
nightly vs. on 
demand
No pure placebo arm
Montorsi 
et al. [173]
423 (≤68 years; 
IIEF-EF ≥ 22; PSA 
<10 ng/mL; GS < 8. 
Bilateral NS; mean 
age 57.9 years
Tadalafil × 9 
months
5 mg daily vs. 
20 mg PRN; 6 week 
washout, then 3 
months open-label 
5 mg daily
13.5 
months
IIEF-EF ≥ 22 after 
6-week washout; 
penile length loss
20.9, 16.9, 19.1% 
IIEF-EF ≥ 22 (daily, 
on demand, placebo) 
after washout—non-
signif; 5 mg daily 
better IIEF-EF vs. 
placebo
“Unassisted 
EF was not 
improved after 
cessation of 
active therapy 
for 9 month.”
Reduced penile 
length loss 
in 5 mg daily 
(difference 4 
mm)
Binary definition 
of success limited 
power; patients with 
mild ED (IIEF-EF 
22–25) were included
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Author Patients Study drug Study schema F/U Outcome metric Findings Conclusion Limitations
Canat 
et al. [174]
129; mean age 63 
years; IIEF-6 no or 
mild ED; bilateral 
NS
Tadalafil × 
12 weeks
20 mg TIW vs. 
20 mg PRN vs. 
placebo at time of 
catheter removal
6 
weeks, 
12 
months
IIEF-6 score at 
6 weeks and 12 
months
6 weeks no diff; 12 
months, higher IIEF 
for TIW group (19.9 
vs 15.8 vs. 13.47; 
TIW, PRN, none)
20 mg TIW is 
effective and 
well-tolerated
Lack of placebo
Kim et al. 
[175]
97; SHIM ≥ 21 and 
RigiScan >60% × 10 
minutes nocturnal 
erection; b/l NS 
(robo-, open); 
mean age 54 years
Sildenafil × 
12 months
50 mg starting night 
after surgery vs. 
placebo; all patients 
received 6 tabs × 100 
mg/months PRN
13 
months
IIEF; RigiScan RigiScan 40% 
potency at 13 months 
for both groups; IIEF 
> 21 29% vs. 32.4%, 
non-significant
No difference for 
50 mg nightly 
sildenafil vs. 
100 mg PRN
76% compliance; 
under accrual; lack of 
true placebo arm
Jo et al. 
[124]
120; >50 years; 
IIEF-5 ≥ 17; 
NS-eligible but not 
always performed; 
s/p RALP 
(~82%);mean age 
63.7 years
Sildenafil × 
12 months
Sildenafil 100 mg 2×/
week after catheter 
removal × 3 months; 
delayed group 
started at 3 months 
post-op; then PRN 
12 months therapy
12 
months
IIEF ≥ 12 months IIEF ≥ in 41.4% vs. 
17.7% (early vs. late); 
PRN usage similar 
between groups
Early sildenafil 
improved full EF 
recovery during 
12 months 
post-RP
Early group younger 
(61.7 vs. 65.6); small 
study
TIW = three times per week; RCT = randomized controlled trial; ICI = intracavernosal injection; f/u = follow-up; NS = nerve sparing; IIEF = International Index of Erectile 
Function; EF = erectile function; PRN = pro re nata (“on demand”); RRP = radical retropubic prostatectomy; MIS = minimally invasive surgery; RP = radical prostatectomy; 
EPIC = Expanded prostate cancer index composite; EF = Erectile function; PSA = prostate specific antigen; REF = Residual Erection Function; RALP = robotic-assisted 
laparoscopic prostatectomy.
Table 1. Randomized controlled trials of post-prostatectomy pharmacologic penile rehabilitation.
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A majority of these trials for ED after radical prostatectomy examine daily vs. on-demand 
dosing schedules. Of note, a randomized, double-blind trial (RESTORE study) in men with 
mild to moderate ED (IIEF-EF 15–20; not post-prostatectomy) of 10 mg vardenafil daily vs. PRN 
showed no differences in increase of IIEF-EF score [126]. Similar findings appear to be borne 
out in the post-RP series as well (see below). Side effect profiles of the treatment groups were 
largely favorable and usually without the need for drug discontinuation. Furthermore, daily 
vs. on demand schedules did not have significantly different adverse effects in a recent meta-
analysis, and absolute rates of side effects were not substantially different between treatment 
and placebo groups overall (59.6% vs. 48.4%) [127]. Side effects generally reported included 
headache, flushing, dyspepsia, and rhinitis, none of which are severe.
6.2.2. Intraurethral prostaglandin
Intraurethral alprostadil (Medicated Urethral System for Erection, MUSE™) has also been 
developed for use in erectile dysfunction. Experience with this drug for non-post-RP erectile 
dysfunction has been limited by lack of efficacy and penile pain/dysuria in a large number of 
patients. Early experience with MUSE after 6 months of post-RP ED showed 55% of the n = 54 
patients able to achieve erections suitable for penetration, although only 48% continued long-
term therapy (57% of men discontinued therapy for inefficacy) [128]. The author’s experience 
with application of the therapy at 3 weeks post-op for a duration of 6 months showed erections 
firm enough for penetration in 74% of patients compliant with treatment. All patients reported 
mild penile pain or urethral burning and 32% of patients discontinued treatment [129].
6.3. Pelvic floor PT
The role of pelvic floor physical therapy (PFMT; “Kegel” exercises) on return of urinary 
continence has been well understood, as evidenced by meta-analyses demonstrating earlier 
return of continence with preoperative PMFT and biofeedback [130, 131]. The impact of such 
therapy on recovery of sexual function has also been explored. Physical therapy efforts focus 
on the bulbocavernosus (bulbospongiosus) and ischiocavernosus muscles. Contraction of the 
ischiocavernosus muscle may compress the proximal aspects of the corpora cavernosa and 
increase intracavernosal pressure during erection [132]. Also, muscle contraction has been 
shown to increase levels of brain-derived neurotrophic factor in muscle cells, which may have 
a role in promoting neuronal growth after nerve injury [133]. A trial of n = 55 men with ED for 
≥6 months randomized one group to PFMT with biofeedback + lifestyle changes vs. lifestyle 
changes alone [134]. Lifestyle changes consisted of alcohol intake reduction, smoking cessa-
tion, increasing exercise, and avoiding bicycle riding. Outcomes were assessed with IIEF and 
anal pressure measurements. At 3 months follow-up, the PFMT group had greater improve-
ment in IIEF than the lifestyle changes alone group (p < 0.001). Other concomitant therapies 
for ED (i.e. PDE5 inhibitors or vacuum erection device) were not disclosed by the authors, lim-
iting the strength of the results. Also, there were no post-prostatectomy patients in this cohort.
With regard to prostatectomy, the timing is such physical therapy is also interesting to con-
sider and there is no established consensus of whether pre- and postoperative physical ther-
apy is superior to postoperative therapy alone. Perez et al. examined the use of biofeedback 
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preoperatively to strengthen the levator muscles prior to radical prostatectomy [135]. Their 
methods employed a device that provided visual feedback based on intra-anal pressures. 
In this prospective cohort study, a total of n = 20 patients completed 10 sessions pre-RP and 
n = 32 patients proceeded directly to surgery. Potency outcomes were assessed using the IIEF-
5, although follow-up time was not clear. The erectile dysfunction rate in the physical therapy 
group was 5% vs. 48.6% in the control group < p < 0.001). There are likely variations in physi-
cal therapy technique and not all methods are standardized.
The impact of PFMT on erectile function after radical prostatectomy has also been examined. 
Prota et al. studied n = 52 patients who underwent open RP and randomized them to PFMT + 
biofeedback weekly × 3 months (beginning at time of catheter removal) vs. verbal instructions 
only [136]. Nerve-sparing was performed in a similar proportion of patients in each group 
(64.7% vs. 68.8%). There was earlier recovery (IIEF >20) in the treatment group which per-
sisted at 12 months post-op (47.1% vs. 12.5%). The authors report an absolute risk reduction 
of 34.6%, with number needed to treat (NNT) of 3. These results are even more encouraging 
given that oral PDE5 inhibitor therapy was withheld during the study. This study provides 
level 1b evidence supporting the use of post-operative PFMT for erectile function recovery 
[136]. Optimal schedule and intensity has yet to be determined.
Additional randomized controlled trials are needed to further assess the utility of PFMT in 
the restoration of potency.
6.4. Novel therapies
6.4.1. Hyperbaric oxygen
The role of hyperbaric oxygen (HBO) in Urology for treatment of radiation-induced hemor-
rhagic cystitis is well known. Application of this technology to post-RP erectile dysfunction is 
controversial. There have been preclinical studies in rats with cavernous nerve injury under-
going HBO that demonstrate higher intracavernosal pressure/mean arterial pressure ratio, 
increased levels of penile nerve growth factor (NGF) and endothelial nitric oxide synthase 
(eNOS) compared to the controls. Tissue studies on smooth muscle to collagen ratio, however, 
did not show a significant difference after HBO [137]. Exposure to 100% oxygen at 2 atm pres-
sure induces stem cell differentiation and neovascularization, as well as vasoconstriction that 
attenuates tissue edema [138]. These findings underlie the rationale for translational studies. 
Chiles et al. published the first randomized, double-blind controlled trial of HBO vs. air for 
men after RP [139]. Although the authors were unable to demonstrate significant difference 
in IIEF score at 18 months, uncertainty about the proper regimen for therapy (total number 
and frequency of treatments) and lack of a true “sham” group may have limited their ability 
to detect a clinically relevant difference in outcome.
6.4.2. Neuroprotective agents
There is a growing body of literature on drug therapy to preempt or mitigate the post-
cavernosal nerve injury pro-inflammatory environment. The immunophilin ligand FK506 
(tacrolimus)—traditionally thought of as an immunosuppressive agent and widely used in 
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for solid organ transplant—has been implicated in a neuroprotective role when administered 
as early as 1 day following partial nerve-crush injury in a rat model [140]. Further work has 
demonstrated improved intracavernous pressure/mean arterial pressure ratio, restoration of 
inducible nitric oxide synthase (iNOS) staining, reduced apoptosis, preservation of caverno-
sal architecture, and upregulation of glutathione peroxidase (GPX) with resultant decrease in 
oxidative-stress-induced tissue damage [141, 142].
Pioglitazone, a thiazolidinedione used for the treatment of diabetes mellitus, may enhance 
neuronal survival and regeneration and decrease inflammation, and has been shown to be 
neuroprotective in models of sciatic nerve ischemia and optic nerve crush injury, as well as 
BCNI [143–145]. Furthermore, a small randomized controlled trial has shown efficacy of this 
agent for erectile dysfunction refractory to sildenafil [146]. A study by Katz et al. investigated 
the impact of pioglitazone on pelvic ganglion neurons after bilateral cavernosal nerve injury 
(BCNI) in Sprague-Dawley rats [147]. Four groups were examined: sham surgery, BCNI, 
BCNI + post-operative pioglitazone, BCNI + pre- and post-operative therapy. Gene expression 
profiles of neuronal nitric oxide synthase, neurturin, glial cell line-derived neurotrophic fac-
tor family receptor alpha-2 (GFRα2), and β-III tubulin were upregulated in the pre-operative 
therapy group [147]. Further work is necessary to fully explore the utility of this therapy.
6.4.3. Amnion-chorion membrane
Dehydrated human amnion-chorion membrane allograft (dHACM) is a source of implant-
able neurotrophic factors and cytokines which promote neural survival and facilitate axonal 
regeneration. Its application has been examined in a rat model of axonal regeneration after 
spinal cord injury [148]. Clinically, it has been applied in the treatment of burns, corneal inju-
ries, chronic venous ulcers, and chronic wounds [149]. There has been preliminary work in 
the placement of this membrane after bilateral nerve-sparing robotic RP to accelerate erectile 
functional recovery after surgery [150]. A single-surgeon propensity-matched analysis of 
preoperatively potent (SHIM >19) and continent (American Urological Association Symptom 
Score < 10) patients (n = 58) demonstrated earlier return of continence (1.2 months vs. 1.8 
months, p = 0.033) and potency (1.34 months vs. 3.39 months, p = 0.007) with the wrap. 
(AmnioFix; MiMedx Group, Marietta, GA, USA) Some limitations of this series include the 
small size, lack of randomization, and short mean follow-up of 4 months, which limits con-
clusions about oncologic safety vis-à-vis risk of biochemical recurrence (BCR). Furthermore, 
functional recovery rates appear much higher than other series in the literature, and may be 
a consequence of the recall bias used to assess level of function. These preliminary results are 
certainly encouraging.
The dHACM allograft wrap was recently examined in a series of n = 940 patients (preoperative 
SHIM > 20) who underwent robotic RP with bilateral nerve-sparing [151]. A total of n = 235 
had bilateral dHACM placement and these were propensity matched in a 1:3 proportion to 
non-dHACM patients (n = 705). Potency recovery rates were higher in the dHACM group at 
all time points except 12 months. Time to potency was significantly shorter in the dHACM 
group after bilateral NS (2.2 months vs. 2.8 months, p = 0.029) and partial NS (3 months vs. 3.9 
months). After 12 months follow-up, erections sufficient for penetration were similar. Of note, 
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the recovery rates in this study were higher than what is generally reported in the literature. 
Also, although the rate of biochemical recurrence at 12 months was similar between groups, 
longer follow-up is certainly needed to demonstrate the oncologic safety of this application 
of technology.
A recent pre-clinical study of the role of hemostatic tissue sealing sheets has also investi-
gated the impact on erectile function recovery in a series of 21 Sprague-Dawley rats [152]. The 
TachoSil (CSL Behring, Tokyo, Japan) is a collagen sponge coated on one side with fibrinogen 
and thrombin and is approved for achieving hemostasis during surgery. Contact between 
the sheet and blood or serosanguinous fluid results in deposition of a fibrin clot. Compared 
to sham surgery, the rats who underwent cavernous nerve dissection and had the TachoSil 
placed demonstrated similar intracavernous pressure/mean arterial pressure ratios at 4 weeks 
post-op. Furthermore, PCR-measured expression of inflammatory and oxidative markers 
(internleukin-6, tumor growth factor beta1, and heme-oxygenase-1) in the major pelvic gan-
glion was significantly reduced in the sheet group (p < 0.05).
6.4.4. Stem cell therapy
Stem cells may be harvested from growing embryos (embryonic stem cells) or as allografts from 
bone marrow or adipose tissue (mesenchymal stem cells). This technology has been applied to 
rat models of bilateral cavernosal nerve crush injury and shown considerable promise. Bochinski 
et al. [153] conducted a study of embryonic stem cells induced along the neuronal cell line with 
brain-derived neurotrophic factor [153]. These stem cells were then injected into the major pelvic 
ganglion (MPG) (group 3) and into the corpora cavernosa (group 4) of rats after BCNI. The 
study was well controlled with sham surgery (group 1) as well as a BCNI group with injection 
of culture media only (group 2). Volume of stem cells injected was 500 μL of a 10,000 cells/
mL solution. Erectile response was assessed by electrostimulation of the cavernosal nerve at 3 
months. Immunohistochemistry was also performed of the penile tissue to assess levels of nitric-
oxide synthase-containing fibers and neurofilament concentration. Intracavernosal pressure in 
response to electrostimulation was greatest for sham surgery and lowest for group 2, which 
was also significantly lower than groups 3 and 4. The neurofilament stain of tissue taken from 
the MPG and the corpus cavernosum was also greater in groups 3 and 4 compared to group 2 
(Figure 12). Such neurofilaments are involved in establishing tensile strength and putatively 
intracellular transport guidance to axons and dendrites [154]. The authors conclude that preser-
vation of the neuronal architecture may promote/facilitate nerve regeneration after nerve injury.
There have been several more studies investigating the role of stem cells in BCNI in rats, either 
alone [155] or in combination with PDE5 inhibitors [156, 157]. Furthermore, Lin et al. reported 
that adipose-derived stem cells (ADSCs) injected into the corpora cavernosa migrated within 
days to the bone marrow and then to the MPG [158]. Subsequent work has been reexamined 
in multiple systematic reviews and meta-analyses, reiterating the efficacy of these methods in 
12 studies, n = 319 rats and 20 studies, n = 248 rats, respectively [159, 160]. The combination of 
stem cells + PDE5 inhibitor therapy appears to have the greatest effect [159]. Consistent out-
comes among the studies were increase in the ICP/MAP ratio, levels of neuronal nitric oxide 
synthase, cavernous smooth muscle content, ratio of cavernous smooth muscle to collage, 
and cGMP levels [160]. Furthermore, stem cells modified by growth or neurotrophic factors 
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prior to implantation appeared to exert the greatest benefit [160]. Although there are many 
processing steps to refine and standardize, this approach remains a riveting endeavor in the 
arena of penile rehabilitation.
7. Penile prosthesis implantation
Despite these advances in the restoration of endogenous erectile function after radical pros-
tatectomy, some men will have dysfunction refractory to the above treatments. The final 
line treatment option for such patients is insertion of a penile prosthesis, which may in fact 
be conceived as a type of mechanotherapy. This procedure eliminates the possibility of any 
Figure 12. Neurofilament staining in major pelvic ganglion (MPG) of rats after bilateral cavernosal nerve crush injury 
(BNCI). A. Sham surgery. B. BCNI alone C. BCNI + neuronal stem cells injected into corpora cavernosa. Reprinted from 
Bochinski et al. [153].
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spontaneous erectile function in the future and has many potential complications, including 
pain, erosion, extrusion, infection, mechanical failure, need for revision, and altered penile 
sensation. There have been a number of surgical improvements that have reduced the infection 
rate, including the “no touch” technique, standardized protocols for perioperative antibiotics, 
and the development of antibiotic-impregnated and hydrophilic devices [161–164]. Although 
the technique of 3-piece penile prosthesis insertion is beyond the scope of this chapter, there 
are a number of considerations with regard to radical prostatectomy. The cavernosal smooth 
muscle fibrosis and penile shortening can have an impact on the size of the cylinders able to 
be accommodated by the corpora, leading to actual or perceived reduction in penile length. 
Furthermore, the lack of glans tumescence with cylinder expansion may exacerbate the per-
ceived loss of size. After appropriate dilation of the corporal bodies with the dilators, fibrosis 
should not preclude placement of a three-piece inflatable prosthesis, which has been reported 
to have the highest satisfaction rates and lowest rate of mechanical failure [165]. Some models 
of the 3-piece prosthesis (i.e. American Medical Systems, AMS 700 CX) allow for cylinder 
axial expansion to allow girth. This is important for men with penile plaques/Peyronie’s dis-
ease and penile curvature that must be corrected during placement of the prosthesis [164]. 
Although not previously discussed, Peyronie’s disease is another “sexual” complication of 
radical prostatectomy, thought to be from repetitive “buckling” injury to the phallus as a 
result of intercourse in the setting of an incomplete erection.
Reservoir placement during the three-piece prosthesis surgery also deserves consideration, 
given the previous dissection of the space of Retzius during the prostatectomy. Given the 
increased risk of bladder perforation, bowel and vascular injury in this setting, some authors 
favor ectopic reservoir placement just posterior to the rectus muscle and anterior to the trans-
versalis fascia [166, 167]. Single-institution series have reported excellent outcomes with this 
approach [166, 167].
Satisfaction with this treatment appears favorable, as exemplified in a recent study of n = 71 
patients who underwent penile prosthesis implantation after radical prostatectomy [168]. 
Pillay et al. employed the EDITS and SEAR questionnaires, as well as the Prostate Cancer-
Related Quality of Life Scale and Patient Health Questionnaire-9 (PHQ-9) for both patients and 
their partners. They reported good sexual function (EPID score > 60) in 77% of men and treat-
ment satisfaction in 94% (EDITS score > 50). Other studies have actually reported improved 
satisfaction for men undergoing early penile prosthesis insertion compared to those receiving 
sildenafil or intracavernosal injection therapy 6 months after radical prostatectomy [169, 170]. 
Such studies did not employ early aggressive pharmacologic penile rehabilitation programs, 
however. Certainly, for the appropriately selected patient, penile prosthesis implantation has 
a very high level of success and satisfaction for patients and their partners alike.
8. Conclusions
There have been many advances in the understanding of erectile dysfunction as a result of 
radical prostatectomy since the initial pioneering work by Walsh & Donker almost 40 years 
ago. Refined understanding of neuroanatomy, beneficial modifications in surgical technique, 
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the advent of robotic surgery, and the exploration of pre- and post-operative rehabilitation 
techniques using mechanotherapy and pharmaceuticals have improved the prognosis for 
potency recovery after this once morbid surgery. Further developments in the realm of local 
and systemic therapies for cavernous nerve neuroprotection and regeneration may mitigate 
the cascade of cavernosal smooth muscle apoptosis, fibrosis, and veno-occlusive dysfunction 
that jeopardizes further erectile function recovery after the period of post-operative neura-
praxia. Achievement of the Trifecta is extremely important to patients and clinicians alike, 
and will surely inspire the future waves of investigations that continue to elucidate this field.
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